Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Tirzepatide on Alcohol Pharmacokinetics
NCT07758231Phase 1Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in obesity, sponsored by University of Wisconsin–Madison. Primary endpoints: Maximum Ethanol Concentration at 350 minutes, Time to Maximum Ethanol Concentration at 350 minutes and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07758231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758231.